Promoting α-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments

Biotechnology Progress

Volumn 25, Issue 4, 2009, Pages 1054-1063

  Kasturirangan, Srinath ^a   Brune, Dan ^b   Sierks, Michael ^a  

^a Arizona State University   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Affinity maturation; Alpha secretase; Beta amyloid; Proteolytic antibody; Single chain antibody

Indexed keywords

AFFINITY MATURATION; ALPHA-SECRETASE; BETA-AMYLOID; PROTEOLYTIC ANTIBODY; SINGLE CHAIN ANTIBODY;

AMINES; AMINO ACIDS; CATALYST ACTIVITY; ELECTROCHEMICAL SENSORS; GLYCOPROTEINS; ORGANIC ACIDS; SITE SELECTION; YEAST;

ANTIBODIES;

AMYLOID BETA PROTEIN; RECOMBINANT PROTEIN; SECRETASE;

ALZHEIMER DISEASE; CATALYSIS; CELL LINE; CHEMISTRY; CONFERENCE PAPER; ENZYMOLOGY; GENETICS; HUMAN; HYDROLYSIS; IMMUNOGLOBULIN VARIABLE REGION; KINETICS; METABOLISM; PROTEIN ENGINEERING; YEAST;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; CATALYSIS; CELL LINE; HUMANS; HYDROLYSIS; IMMUNOGLOBULIN VARIABLE REGION; KINETICS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; YEASTS;

EID: 69149096041     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1002/btpr.190     Document Type: Conference Paper

References (57)

1. Apostolova LG, Thompso PM. Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. Neuropsychologia. 2008; 46: 1597-1612.
2. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007; 8: 101-112.
3. Nicoll JA, Wilkinson D, Holmes C, Steart, P, Markham, H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003; 9: 448-452.
4. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature. 2002; 415: 462.
5. Chander H, Chauhan A, Chauhan V. Binding of proteases to fibrillar amyloid-beta protein and its inhibition by Congo red. J Alzheimers Dis. 2007; 12: 261-269.
6. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA. 2003; 100: 4162-4167.
7. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 2008; 18: 240-252.
8. Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM. Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis. 2008; 31: 442-450.
9. Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J Biol Chem. 2000; 275: 36621-36625.
10. Gao QS, Sun M, Tyutyulkova S, Webster D, Rees A, Tramontano A, Massey RJ, Paul S. Molecular cloning of a proteolytic antibody light chain. J Biol Chem. 1994; 269: 32389-32393.
11. Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry. 2003; 42: 14328-14334.
12. Sun M, Gao QS, Kirnarskiy L, Rees A, Paul S. Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain. J Mol Biol. 1997; 271: 374-385.
13. Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL, Rollence ML, Wood JF, Schott ME, Milenic DE. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 1993; 6: 989-995. (Pubitemid 23347376)
14. Shan D, Pres OW, Tsu TT, Hayden MS, Ledbetter JA. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J Immunol. 1999; 162: 6589-6595.
15. Xu JL, Davis MM. Diversity in the CDR3 region of V (H) is sufficient for most antibody specificities. Immunity. 2000; 13: 37-45.
16. Wang XX, Shusta EV. The use of scFv-displaying yeast in mammalian cell surface selections. J Immunol Methods. 2005; 304: 30-42.
17. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc. 2006; 1: 755-768.
18. Feldhaus MJ, Siegel RW. Yeast display of antibody fragments: a discovery and characterization platform. J Immunol Methods. 2004; 290: 69-80.
19. Yeung YA, Wittrup KD. Quantitative screening of yeast surface-displayed polypeptide libraries by magnetic bead capture. Biotechnol Prog. 2002; 18: 212-220.
20. Xu Y, Yamamoto N, Janda KD. Catalytic antibodies: hapten design strategies and screening methods. Bioorg Med Chem. 2004; 12: 5247-5268.
21. Tanaka F. Catalytic antibodies as designer proteases and esterases. Chem Rev. 2002; 102: 4885-4906.
22. Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, Hanson C, Nishiyama Y. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem. 2003; 278: 20429-20435.
23. Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S. Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun Rev. 2008; 7: 473-479.
24. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev. 2008; 7: 391-397.
25. Gao C, Mao S, Kaufmann G, Wirsching P, Lerner RA, Janda KD. A method for the generation of combinatorial antibody libraries using pIX phage display. Proc Natl Acad Sci USA. 2002; 99: 12612-12616.
26. Bond CJ, Marsters JC, Sidhu SS. Contributions of CDR3 to V H H domain stability and the design of monobody scaffolds for naive antibody libraries. J Mol Biol. 2003; 332: 643-655.
27. Orr-Weaver TL, Szostak JW. Yeast recombination: the association between double-strand gap repair and crossing-over. Proc Natl Acad Sci USA. 1983; 80: 4417-4421.
28. Fujita Y, Ito J, Ueda M, Fukuda H, Kondo A. Synergistic saccharification, and direct fermentation to ethanol, of amorphous cellulose by use of an engineered yeast strain codisplaying three types of cellulolytic enzyme. Appl Environ Microbiol. 2004; 70: 1207-1212.
29. Siegel RW, Coleman JR, Miller KD, Feldhaus MJ. High efficiency recovery and epitope-specific sorting of an scFv yeast display library. J Immunol Methods. 2004; 286: 141-153.
30. Nishiyama Y, Taguchi H, Luo JQ, Zhou YX, Burr G, Karle S, Paul S. Covalent reactivity of phosphonate monophenyl esters with serine proteinases: an overlooked feature of presumed transition state analogs. Arch Biochem Biophys. 2002; 402: 281-288.
31. Komano H, Rockwell N, Wang GT, Krafft GA, Fuller RS. Purification and characterization of the yeast glycosylphosphatidylinositol-anchored, monobasic-specific aspartyl protease yapsin 2 (Mkc7p). J Biol Chem. 1999; 274: 24431-24437.
32. Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ. Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. Protein Expr Purif. 2005; 42: 255-267.
33. Zameer A, Kasturirangan S, Emadi S, Nimmagadda SV, Sierks MR. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J Mol Biol. 2008; 384: 917-928.
34. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lu L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21: 383-421.
35. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jorda WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB. Exacerbation of cerebral amyloid angiopathyassociated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005; 25: 629-636.
36. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenber GD, Ji LW, Kovacina KS, Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol. 2003; 162: 313-319.
37. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisn MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998; 273: 32730-32738.
38. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003; 40: 1087-1093.
39. Leissring MA, Selkoe DJ. Structural biology: enzyme target to latch on to. Nature. 2006; 443: 761-762.
40. Llovera RE, de Tullio M, Alonso LG, Leissring MA, Kaufman SB, Roher AE, de Prat Gay G, Morelli L, Castano EM. The catalytic domain of insulin-degrading enzyme forms a denaturantresistant complex with amyloid beta peptide: implications for Alzheimer's disease pathogenesis. J Biol Chem. 2008; 283: 17039-17048.
41. Arafat WO, Gomez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN, Siegal GP, Alvarez RD, Hemminki A, Nettelbeck DM, Curiel DT. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther. 2002; 9: 256-262.
42. Kim SH, Schindler DG, Lindner AB, Tawfik DS, Eshhar Z. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies. Mol Immunol. 1997; 34: 891-906.
43. Clark M. Antibody humanization: a case of the "Emperor's new clothes"? Immunol Today. 2000; 21: 397-402.
44. Kim DJ, Chung JH, Ryu YS, Rhim JH, Kim CW, Suh Y, Chung HK. Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas. Br J Cancer. 2002; 87: 405-413.
45. Argos P. An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J Mol Biol. 1990; 211: 943-958.
46. Tominaga T, Hatakeyama Y. Determination of essential and variable residues in pediocin PA-1 by NNK scanning. Appl Environ Microbiol. 2006; 72: 1141-1147.
47. Noel D, Bernardi T, Navarro-Teulon I, Marin M, Martinetto JP, Ducancel F, Mani JC, Pau B, Piechaczyk M, Biard-Piechaczyk M. Analysis of the individual contributions of immunoglobulin heavy and light chains to the binding of antigen using cell transfection and plasmon resonance analysis. J Immunol Methods. 1996; 193: 177-187.
48. Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, Chien Y. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol. 1998; 16: 523-544.
49. Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol. 1987; 196: 901-917.
50. Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbroodt S, Hogan S, Rem L, Frans N, Daukandt M, Pieters H, van Hegelsom R, Neer NC, Nastri HG, Rondon IJ, Leeds JA, Hufton SE, Huang L, Kashin I, Devlin M, Kuang G, Steukers M, Viswanathan M, Nixon AE, Sexton DJ, Hoogenboom HR, Ladner RC. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol. 2002; 3: 344-348.
51. Taguchi H, Burr G, Karle S, Planque S, Zhou YX, Paul S, Nishiyama Y. A mechanism-based probe for gp120-Hydrolyzing antibodies. Bioorg Med Chem Lett. 2002; 12: 3167-3170.
52. Liu R, McAllister C, Lyubchenko Y, Sierks MR. Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry. 2004; 43: 9999-10007.
53. Gao QS, Sun M, Rees AR, Paul S. Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol. 1995; 253: 658-664.
54. Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res. 2007; 4: 412-417.
55. Postina R. A closer look at alpha-secretase. Curr Alzheimer Res. 2008; 5: 179-186.
56. Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Sci. 1995; 4: 337-360.
57. Olsen JV, Ong SE, Mann M. Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol Cell Proteomics. 2004; 3: 608-614.